XML 36 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
SHAREHOLDERS' EQUITY
 12 Months Ended
Dec. 31, 2023
Stockholders' Equity Note [Abstract]  
SHAREHOLDERS' EQUITY
NOTE 13: -
SHAREHOLDERS' EQUITY
 
  a.
Company's shares:
 
As of December 31, 2023, the Company's authorized share capital consists of NIS 20,000,000 divided into 200,000,000 Ordinary Shares, par value NIS 0.1 per share. Ordinary Shares confer on their holders the right to receive notice to participate and vote in general meetings of the Company, the right to a share in the excess of assets upon liquidation of the Company, and the right to receive dividends if declared.
 
  b.
Share option plan:
 
A summary of the Company's share option activity, pertaining to its option plans for employees and related information is as follows:
 
   
Year ended December 31,
  
   
2023
    
2022
    
2021
  
   
Number
of shares upon exercise
    
Weighted average exercise price
    
Number
of shares upon exercise
    
Weighted average exercise price
    
Number
of shares upon exercise
    
Weighted average exercise price
  
                                     
Outstanding at beginning of year
    
487,839
    
$
5.96
      
675,986
    
$
7.99
      
1,134,256
    
$
7.68
  
Forfeited
    
(72,480
)
  
$
9.04
      
(139,494
)
  
$
16.08
      
(30,861
)
  
$
16.78
  
Exercised
    
(1,364
)
  
$
0.03
      
(48,653
)
  
$
5.01
      
(427,409
)
  
$
6.54
  
                                                 
Outstanding at end of year
    
413,995
    
$
5.44
      
487,839
    
$
5.96
      
675,986
    
$
7.99
  
                                                 
Exercisable at end of year
    
413,995
    
$
5.44
      
487,839
    
$
5.96
      
660,986
    
$
8.04
  
                                                 
Vested and expected to vest
    
413,995
    
$
5.44
      
487,839
    
$
5.96
      
675,584
    
$
7.99
  

 

The aggregate intrinsic value represents the total intrinsic value (the difference between the Company's closing share price on the last trading day of the fiscal years 2023, 2022 and 2021 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders if all option holders exercised their options on December 31, 2023, 2022 and 2021, respectively. This amount may change based on the fair market value of the Company's share. The total intrinsic value of options outstanding as of December 31, 2023, 2022 and 2021, were $ 0, $ 10 and $ 3,481, respectively.
 
The total intrinsic value of exercisable options as of December 31, 2023, 2022 and 2021, were approximately $ 1, $ 10 and $ 3,392 , respectively. The total intrinsic value of options vested and expected to vest as of December 31, 2023, 2022 and 2021, were approximately $ 0, $ 10 and $ 3,479, respectively. The total intrinsic value of options outstanding as of December 31, 2023, 2022 and 2021, were approximately $ 0, $ 10 and $ 3,481, respectively.
 
The total intrinsic value (the difference between the Company's closing share price on the exercise date and the exercise price) of options exercised during the years ended December 31, 2023, 2022 and 2021 were approximately $ 93, $ 93 and $ 4,113 , respectively. The number of options vested during the year ended December 31, 2023, was 0. The weighted-average remaining contractual life of the outstanding options as of December 31, 2023, is 0.51 years. The weighted-average remaining contractual life of exercisable options as of December 31, 2023, is 0.51 years.
 
The following provides a summary of the restricted share unit activity for the Company for the two years ended December 31, 2023:
 
   
Year ended December 31,
  
   
2023
    
2022
  
   
Number
of shares upon exercise
    
Weighted average share price
    
Number
of shares upon exercise
    
Weighted average share price
  
                         
Outstanding at beginning of year
    
2,255,620
    
$
8.52
      
1,937,908
    
$
12.92
  
Granted
    
1,330,500
    
$
2.47
      
1,473,400
    
$
5.22
  
Vested
    
(1,005,532
)
  
$
2.19
      
(829,910
)
  
$
15.82
  
Forfeited
    
(316,889
)
  
$
2.38
      
(325,778
)
  
$
5.78
  
                                 
Unvested at end of year
    
2,263,699
    
$
4.95
      
2,255,620
    
$
8.52
  

 

As of December 31, 2023, $ 8,134,803 unrecognized compensation cost related to RSUs is expected to be recognized over a weighted average vesting period of 1.62 years.
 
Under the terms of the above option plans, options may be granted to employees, officers, directors and various service providers of the Company and its subsidiaries. The options vest over a four-year period, subject to the continued employment of the employee. The options generally expire no later than ten years from the date of the grant. The exercise price of the options at the date of grant under the plans may not be less than the nominal value of the shares into which such options are exercised, any options, which are forfeited or cancelled before expiration, become available for future grants. As of December 31, 2023, 252,548 Ordinary shares are available for future issuance under the option plans.
 
The Company granted 1,330,500 and 1,473,400 RSUs in 2023 and 2022, respectively under the 2016 option plan. RSUs vest over a period of between three to four years, subject to the continued employment of the employee. RSUs that are cancelled or forfeited become available for future grants.